Abstract
Francisella philomiragia is a very uncommon pathogen of humans. Diseases caused by it are protean and have been reported largely in near-drowning victims and those with chronic granulomatous disease. We present a case of F. philomiragia pneumonia with peripheral edema and bacteremia in a renal transplant patient and review the diverse reports of F. philomiragia infections.
CASE REPORT
A 63-year-old female from Indiana presented to an Indianapolis hospital with worsening shortness of breath, nonproductive cough, and increasing bilateral peripheral edema. The patient was afebrile, normotensive, and normocardic but was tachypnic (40 bpm) and denied having fevers, chills, or other symptoms of an infectious process while at home. Significant medical history obtained at the time of presentation included a renal transplant secondary to polycystic kidney disease 14 years prior for which she receives chronic immunosuppressive therapy (tacrolimus and prednisone). The patient did not report recent travel outside Indiana, exposure to wild animals or recreational water sources, or exposure to sick individuals. Because of the possibility of acute transplant rejection, the patient was admitted to the intensive care unit for extensive evaluation. A chest X-ray performed at the time of admission revealed bilateral perihilar and upper-lobe infiltrates consistent with bilateral bronchopneumonia, prompting the collection of a set of blood cultures from the left arm and of another set from the right arm and initiation of empirical broad-spectrum antimicrobial therapy with vancomycin and piperacillin-tazobactam. Aside from blood cultures, no other microbiology testing was performed. Laboratory studies conducted at the time of admission revealed leukocytosis (11,600 cells/μl) with 93% neutrophils, anemia (3.32 million cells/μl), kidney failure (elevated levels of urea nitrogen [48 mg/dl] and creatinine [3.70 mg/dl]), and hyperglycemia (127 mg of glucose/dl). Elevated levels of procalcitonin (1.86 ng/ml), hematuria (25 cells/μl), and proteinuria (500 mg/dl) were also noted. Because of the possibility of acute-on-chronic kidney disease, a renal biopsy was subsequently performed, and it revealed acute allograft rejection.
Following approximately 24 h of incubation in a continuous-monitoring blood culture instrument (BD Bactec 9240; BD Diagnostic Systems, Sparks, MD), the aerobic bottles from both sets of blood cultures signaled positively. Gram stains of broth from both bottles revealed pleomorphic, Gram-negative coccobacilli (Fig. 1A). Subcultures of the blood culture broth grew medium-sized (∼5-mm diameter), glossy, convex colonies resembling a member of the Enterobacteriaceae on sheep blood and chocolate agars after 48 h of incubation at 35°C in 5% CO2. A Gram stain of the colonies revealed organisms with morphologies identical to those seen in the blood culture broth smear. The isolate tested positive for cytochrome oxidase and catalase. Together, these observations ruled out possible select agents, including Francisella tularensis and Brucella spp., so enhanced biosafety precautions were not implemented. Conventional tubed biochemical testing of the isolate did not result in an identification, and automated phenotypic testing (Vitek 2 GNI card; bioMérieux) yielded disparate identifications, including Aggregatibacter aphrophilus, Pseudomonas aeruginosa, and Sphingomonas paucimobilis. Subsequently, triplicate analysis of the isolate by both matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (research-use-only [RUO] library iteration 4613, spring 2013; Bruker Daltonics, Billerica, MA) and fatty acid methyl ester analysis by gas chromatography (Sherlock MIS; MIDI, Inc., Newark, DE) yielded an identification of Francisella philomiragia. For the former, top score values above 2.200 were obtained for each of three analyses using standard techniques, and all top identification matches corresponded to all 6 mass spectral profiles (MSP) of F. philomiragia isolates incorporated into the MSP library. Sequencing of a 1,448-bp region of the 16S rRNA gene as previously described (1) confirmed the identification as F. philomiragia (Fig. 1B). Following isolate identification, the patient was started on a 2-week course of doxycycline therapy, which was based upon treatment recommendations for tularemia, since the clinicians were unfamiliar with the treatment options for F. philomiragia infections. Upon completion of antimicrobial chemotherapy, the patient was well enough to be discharged to home. Prior to discharge, however, the patient received a tunneled dialysis catheter and underwent hemodialysis to compensate for decreased renal allograft function. Follow-up blood cultures were negative, and, to date, the patient has not reported infection recrudescence. The source of the patient's infection remains unknown, as none of the previously reported routes of exposure (see below) were noted. In addition, the patient denied receipt of medical treatment involving aerosolized instillation of aqueous medications or recreational water exposure.
Fine-scale phylogenetic analysis of the isolate was performed by multilocus sequence typing (MLST) using gene targets gyrB, metG, the AKIII gene, and glpK as follows: (i) for the AKIII gene, GAAGAAATTATAGAACAGGT and AGCATCTGAACCAATAAACCCT; (ii) for gyrB, AGCTCTATCAGAAGTCAGAA and AGATCTTCATAATCCTTAGT; (iii) for metG, AGCTCAAGCGTATGATCCTG and GTTTTTGTCACAGTAATCTCT; (iv) for metG, TAAACCAACCTATGCTTTAG and ATTGGAATTGCATCAAGAAA ; (v) for tyr, ATGCTTAGTATCATACAAAG and CCTTAAAAGTAAAAGTTACAGG; (vi) for adh, CAGATTGTTGGTGTTGATAC and CTATCAATATCAATACGACC. An identification of F. philomiragia subspecies philomiragia was indicated by MLST (Fig. 1C). Reference sequences were obtained from GenBank (2), and phylogenetic trees were generated using Clustal Omega (3) and visualized using iTOL 2.0 (4). Conventional biochemical analysis and antimicrobial susceptibility testing (AST) by broth microdilution of this clinical isolate (14IUHPL001) and the type strain of the species, F. philomiragia subsp. philomiragia FSC144T, were performed in parallel, and the results are summarized in Table 1.
TABLE 1.
Biochemical reaction or antimicrobial agent(s)a | Result or MIC (μg ml−1) |
|
---|---|---|
FSC114T | 14IUHPL001 | |
Biochemical reaction | ||
Catalase | + | + |
Oxidase | + | + |
Indole | − | − |
Methyl red | − | − |
Voges-Proskauer | − | − |
Citrate utilization | − | − |
Nitrate reduction | − | − |
Gelatin hydrolysis | − | − |
Urease | − | − |
Motility | − | − |
Arginine hydrolysis | − | − |
Lysine decarboxylation | − | − |
Ornithine decarboxylation | − | − |
Malonate | − | − |
DNase | − | − |
β-Lactamase (nitrocefin disk) | + | + |
H2S production (TSI medium) | + | + |
Acid from d-glucose | + | + |
Acid from glycerol | − | − |
Acid from lactose | − | − |
Acid from maltose | − | − |
Acid from sucrose | − | − |
Antimicrobial agent(s) | ||
Amikacin | ≤0.5 | ≤0.5 |
Amoxicillin-clavulanic acid | 1 | 1 |
Ampicillin | 32 | 32 |
Aztreonam | 4 | 2 |
Cefepime | 4 | 1 |
Ceftazidime | ≤0.5 | ≤0.5 |
Ceftriaxone | ≤0.5 | ≤0.5 |
Cefazolin | 2 | 16 |
Ciprofloxacin | ≤0.25 | ≤0.25 |
Colistin | >8 | >8 |
Doripenem | ≤0.25 | ≤0.25 |
Doxycycline | ≤1 | ≤1 |
Ertapenem | ≤0.25 | ≤0.25 |
Erythromycin | 1 | 2 |
Gentamicin | ≤0.5 | ≤0.5 |
Imipenem | ≤0.25 | ≤0.25 |
Levofloxacin | ≤2 | ≤2 |
Meropenem | ≤0.25 | ≤0.25 |
Moxifloxacin | ≤0.25 | ≤0.25 |
Oxacillin | ≤0.25 | >16 |
Polymyxin B | >4 | >4 |
Ticarcillin-clavulanic acid | ≤4 | ≤4 |
Tigecycline | ≤0.25 | ≤0.25 |
Tobramycin | ≤0.5 | ≤0.5 |
Trimethoprim-sulfamethoxazole | >4 | >4 |
Antimicrobial susceptibility testing was performed by broth microdilution using cation-adjusted Mueller-Hinton broth incubated in an ambient atmosphere at 35°C for 24 h. TSI, triple sugar iron.
This report describes a case of F. philomiragia-associated pneumonia in a patient receiving chronic immunosuppressive therapy secondary to renal allograft, as well as acute-on-chronic kidney disease and acute allograft rejection in the absence of known risk factors (e.g., exposure to an aquatic environment). Fortunately, the pathogen was rapidly identified and antimicrobial chemotherapy, which was based upon treatment recommendations for Francisella tularensis infections, was initiated. To our knowledge, F. philomiragia pulmonary infection and bacteremia in a renal transplant patient has never been reported until now.
Francisella philomiragia, a close relative of Francisella tularensis, is a rarely encountered opportunistic bacterial pathogen of humans. However, it is an important cause of francisellosis in wild and farmed fish. Because human diseases caused by this organism are not nationally notifiable, trends in its incidence and prevalence are unknown. Identification of this organism requires methods beyond the scope of many community hospital microbiology laboratories, and such facilities are encouraged to refer isolates to state health department laboratories or commercial reference laboratories. F. philomiragia is well represented in the Bruker MALDI Biotyper RUO library, so laboratories employing this technology can obtain a confident identification without further testing. Seibold et al. have reported the reliability and robustness of mass spectrometry-based identification of francisellae, including F. philomiragia (5); thus, as this technology becomes more commonly adopted, many laboratories will be able to confidently identify F. philomiragia and other rarely isolated bacteria. However, laboratories should remain diligent with regard to appropriate biosafety and biosecurity practices for isolates that cannot be ruled out as being F. tularensis or another select agent. Up-to-date guidance, including biosafety practices and laboratory methods, from the Laboratory Response Network for ruling out select agents should always be followed.
The taxonomy of F. philomiragia and of francisellae in general has been contentious, and, as a result, review of case literature is challenging. Members of the genus Francisella were originally classified as part of the genus Yersinia (6); therefore, the initial F. philomiragia case reports were published using the epithet Yersinia philomiragia. Upon publication of the genus Francisella, at least one distinct species was condensed into a subspecies of F. tularensis (7), though this recommendation has yet to be validly published and adopted by the International Committee for the Systematics of Prokaryotes. Valid publication of the novel subspecies F. philomiragia subspecies noatunensis forced the renaming of existing strains to F. philomiragia subspecies philomiragia (8). This continual revision of nomenclature indicates that cases associated with this organism have been described in the literature with one of three epithets: Y. philomiragia, F. philomiragia, or F. philomiragia subspecies philomiragia. These discrepancies prompted us to prepare a thorough review of the clinical literature to generate a complete view of the spectrum of clinical presentations associated with this organism (Table 2).
TABLE 2.
Patient sex, age (yrs)a | Patient location/treatment date or report date | Preexisting illness | Clinical presentation | Source of isolate | Clinical outcome | Reference |
---|---|---|---|---|---|---|
M, 18 | California, USA/1974 | CGD | Fever, pneumonia | Lung biopsy specimen | Resolution | 9 |
M, 39 | Colorado, USA/1976 | Chronic pleural effusions | Fever | Pleural fluid | Resolution | 9 |
M, ? | New York, USA/1977 | Near-drowning | Unknown | Blood | Unknown | 9 |
M, 39 | California, USA/1978 | Near-drowning | Fever, pneumonia, brain abscess | Blood | Death | 9 |
M, 6 | Switzerland/? | CGD | Fever, sepsis | Blood, bone marrow, ascitic fluid | Death | 9 |
F, 68 | Pennsylvania, USA/1980 | Agnogenic myeloid metaplasia | Fever | Blood | Resolution | 9 |
F, 86 | Connecticut, USA/1980 | Near-drowning | Fever, pneumonia | Blood | Resolution | 9 |
M, 75 | Connecticut, USA/1980 | Near-drowning | Pneumonia | Blood | Resolution | 9 |
M, 5 | New York, USA/1981 | CGD | Fever | Blood | Unknown | 9 |
F, 12 | California, USA/1981 | CGD | Pneumonia | Lung biopsy specimen | Unknown | 9 |
F, 34 | New Mexico, USA/1984 | None | Peritonitis | Ascitic fluid | Resolution | 9 |
M, 28 | Virginia, USA/1985 | Near-drowning | Sepsis | Blood | Unknown | 9 |
F, 47 | New York, USA/1986 | Hodgkin disease | Fever, sepsis | Pericardial fluid, blood | Resolution | 9 |
M, 16 | Massachusetts, USA/1986 | CGD | Meningitis | Cerebrospinal fluid | Resolution | 9 |
M, 19 | Maryland, USA/1997 | CGD | Fever, sepsis | Blood | Resolution | 10 |
M, 10 | Nova Scotia, Canada/2003 | CGD | Adenitis, pulmonary nodules | Submandibular node | Resolution | 11 |
M, 25 | Turkey/2003 | CGD | Pneumonia | Blood | Death | 12 |
F, 63 | Indiana, USA/2014 | Immunosuppression secondary to renal allograft, chronic kidney disease | Pneumonia | Blood | Resolved | This report |
F, female; M, male.
Human infections with F. philomiragia subspecies philomiragia most often present as pneumonia, but peritonitis, sepsis, and meningitis have also been documented (9–12). Most commonly, F. philomiragia is isolated from patients with underlying immunosuppressive conditions, especially children and young adults with chronic granulomatous disease (CGD). However, several cases of sepsis have been documented in otherwise healthy individuals who were victims of near-drowning in marine and estuary waters. In addition, isolates from both clinical (sepsis, meningitis) and subclinical infections of mammals have been reported. In contrast to F. tularensis, very little is understood about the pathogenesis of F. philomiragia. Since it is most commonly isolated from individuals who have had recent exposure to water, it is postulated that contact with, ingestion of, and/or inhalation of contaminated water may put individuals at risk for infection. However, the patient in this report has no known history of water exposure. Research has demonstrated that F. philomiragia is capable of forming robust biofilms in association with aquatic amoebae and, in prolonged coincubation, is capable of infecting amoebae (13). Such association may permit both the persistence of the organism in the environment and its dissemination to hosts that come in contact with F. philomiragia-infected amoebae via waterway exposure. F. philomiragia subspecies noatunensis appears, at this point, to be exclusively a pathogen of fish.
Clinical outcomes vary widely, ranging from complete resolution with no residual pathology to rapid death. Numerous antimicrobial treatment regimens have been reported with differing rates of resolution. A reported case that included fever and pleuritis resolved without antimicrobial therapy; however, all other reported cases featured treatment with at least two and as many as four antibiotics (9, 11). There is not a standard recommended therapy for F. philomiragia infection, though beta-lactams should be avoided because beta-lactamase production appears to be common (9). It is apparent that disease presentation and prognosis of F. philomiragia infection is case and context dependent, driven by variables that have included antimicrobial agent selection, disease status at the onset of treatment, and underlying conditions. For the first time, we report a case of francisellosis in a renal transplant patient.
ACKNOWLEDGMENT
We thank the Indiana University (IU) Health Pathology Laboratory Division of Clinical Microbiology for help with initial isolation and characterization of the isolate.
REFERENCES
- 1.Weisburg WG, Barns SM, Pelletier DA, Land DJ. 1991. 16S ribosomal DNA amplification for phylogenetic study. J Bacteriol 173:697–703. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Benson DA, Clark K, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. 2015. GenBank. Nucleic Acids Res 43(Database issue):D30–D35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Sievers F, Higgins DG. 2014. Clustal Omega, accurate alignment of very large numbers of sequences. Methods Mol Biol 1079:105–116. doi: 10.1007/978-1-62703-646-7_6. [DOI] [PubMed] [Google Scholar]
- 4.Letunic I, Bork P. 2011. Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res 39(Web Server issue):W475–W478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Seibold E, Maier T, Kostrzewa M, Zeman E, Splettstoesser W. 2010. Identification of Francisella philomiragia by whole-cell matrix-assisted laser desorption ionization-time of flight mass spectrometry: fast, reliable, robust, and cost-effective differentiation on species and subspecies levels. J Clin Microbiol 48:1061–1069. doi: 10.1128/JCM.01953-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Jensen WI, Owen CR, Jellison WL. 1969. Yersinia philomiragia sp. n., a new member of the Pasteurella group of bacteria, naturally pathogenic for the muskrat (Ondatra zibethica). J Bacteriol 100:1237–1241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hollis DG, Weaver RE, Steigerwalt AG, Wenger JD, Moss CW, Brenner DJ. 1989. Francisella philomiragia comb. nov. (formerly Yersinia philomiragia) and Francisella tularensis biogroup novicida (formerly Francisella novicida) associated with human disease. J Clin Microbiol 27:1601–1608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mikalsen J, Olsen AB, Tengs T, Colquhoun DJ. 2007. Francisella philomiragia subsp. noatunensis subsp. nov., isolated from farmed Atlantic cod (Gadus morhua L.). Int J Syst Evol Microbiol 57(Pt 9):1960–1965. doi: 10.1099/ijs.0.64765-0. [DOI] [PubMed] [Google Scholar]
- 9.Wenger JD, Hollis DG, Weaver RE, Baker CN, Brown GR, Brenner DJ, Broome CV. 1989. Infection caused by Francisella philomiragia (formerly Yersinia philomiragia). A newly recognized human pathogen. Ann Intern Med 110:888–892. [DOI] [PubMed] [Google Scholar]
- 10.Sicherer SH, Asturias EJ, Winkelstein JA, Dick JD, Willoughby RE. 1997. Francisella philomiragia sepsis in chronic granulomatous disease. Pediatr Infect Dis J 16:420–422. doi: 10.1097/00006454-199704000-00021. [DOI] [PubMed] [Google Scholar]
- 11.Mailman TL, Schmidt MH. 2005. Francisella philomiragia adenitis and pulmonary nodules in a child with chronic granulomatous disease. Can J Infect Dis Med Microbiol 16:245–248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Friis-Møller A, Lemming LE, Valerius NH, Bruun B. 2004. Problems in identification of Francisella philomiragia associated with fatal bacteremia in a patient with chronic granulomatous disease. J Clin Microbiol 42:1840–1842. doi: 10.1128/JCM.42.4.1840-1842.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Verhoeven AB, Durham-Colleran MW, Pierson T, Boswell WT, Van Hoek ML. 2010. Francisella philomiragia biofilm formation and interaction with the aquatic protist Acanthamoeba castellanii. Biol Bull 219:178–188. [DOI] [PubMed] [Google Scholar]